A pilot study to investigate the bioequivalence of two Roflumilast 500 μg tablet formulations (B and E) in healthy volunteers. A single-centre, single-dose, open label, randomized, four-period change-over phase I study with two replicated treatment sequences and a washout interval of at least 7 days between periods

*Please Note* The Study you are attempting to view was acquired from Takeda by AstraZeneca and was disclosed initially by Takeda per their Transparency Policies. More information regarding this study may be available by contacting [email protected].

An open-label, randomized, four-period crossover, two replicated sequences study in healthy subjects.